内皮素-1与射血分数降低心衰患者预后及达格列净疗效:DAPA-HF研究
本研究基于DAPA-HF试验,分析3048例射血分数降低心衰患者基线内皮素-1(ET-1)水平与预后及肾脏功能的关系,并评估达格列净疗效。结果显示,较高基线ET-1独立关联更差临床结局和肾功能下降加速;达格列净获益不受基线ET-1影响,且使ET-1小幅降低。
要点
- 较高基线ET-1独立关联更差心衰结局和肾功能下降加速。
- 达格列净获益在ET-1各水平组一致。
- 达格列净使ET-1降低0.13 pg/mL(95%CI 0.25-0.01)。
核心结论
- 较高基线ET-1浓度独立关联更差临床结局和肾功能更快速下降。
- 达格列净获益在测量的ET-1浓度范围内一致,且治疗导致血清ET-1小幅降低。
研究设计与样本
- 基于DAPA-HF试验的事后分析,纳入3048例有基线ET-1测量的射血分数降低心衰患者。
- 按基线ET-1三分位分组:T1≤3.28 pg/mL(n=1016)、T2>3.28-4.41 pg/mL(n=1022)、T3>4.41 pg/mL(n=1010)。
主要发现
- 较高ET-1患者更可能为男性、肥胖,左室射血分数更低、估算肾小球滤过率更低、功能状态更差、NT-proBNP和高敏肌钙蛋白T更高。
- 调整Cox模型中,主要结局(心血管死亡或心衰恶化)风险:T3 vs T1 调整HR 1.95(95%CI 1.53-2.50),T2 vs T1 调整HR 1.36(95%CI 1.06-1.75)。
- 估算肾小球滤过率年下降斜率:T3 -3.19(95%CI -3.66至-2.72)mL/min/1.73m²,T2 -2.08(95%CI -2.52至-1.63),T1 -2.35(95%CI -2.79至-1.91),P=0.002。
- 达格列净获益不受基线ET-1影响;安慰剂校正的ET-1降低为0.13 pg/mL(95%CI 0.25-0.01,P=0.029)。
关键数值与推荐
- 基线ET-1三分位阈值:T1≤3.28 pg/mL,T2>3.28-4.41 pg/mL,T3>4.41 pg/mL。
- 主要结局调整HR:T3 vs T1为1.95(95%CI 1.53-2.50),T2 vs T1为1.36(95%CI 1.06-1.75)。
- eGFR年下降斜率:T3 -3.19(95%CI -3.66至-2.72),T2 -2.08(95%CI -2.52至-1.63),T1 -2.35(95%CI -2.79至-1.91),P=0.002。
- 达格列净安慰剂校正ET-1降低0.13 pg/mL(95%CI 0.25-0.01,P=0.029)。
临床怎么用
- 基线ET-1较高提示射血分数降低心衰患者预后更差及肾功能下降风险更高。
- 达格列净疗效不受基线ET-1水平影响,各ET-1水平患者均可获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ET-1 (endothelin-1) is implicated in the pathophysiology of heart failure and renal disease. Its prognostic importance and relationship with kidney function in patients with heart failure with reduced ejection fraction receiving contemporary treatment are uncertain. We investigated these and the efficacy of dapagliflozin according to ET-1 level in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure). METHODS: We investigated the incidence of the primary outcome (cardiovascular death or worsening heart failure), change in kidney function, and the effect of dapagliflozin according to baseline ET-1 concentration, adjusting in Cox models for other recognized prognostic variables in heart failure including NT-proBNP (N-terminal pro-B-type natriuretic peptide). We also examined the effect of dapagliflozin on ET-1 level. RESULTS: Overall, 3048 participants had baseline ET-1 measurements: tertile 1 (T1; ≤3.28 pg/mL; n=1016); T2 (>3.28-4.41 pg/mL; n=1022); and T3 (>4.41 pg/mL; n=1010). Patients with higher ET-1 were more likely male, more likely obese, and had lower left ventricular ejection fraction, lower estimated glomerular filtration rate, worse functional status, and higher NT-proBNP and hs-TnT (high-sensitivity troponin-T). In the adjusted Cox models, higher baseline ET-1 was independently associated with worse outcomes and steeper decline in kidney function (adjusted hazard ratio for primary outcome of 1.95 [95% CI, 1.53-2.50] for T3 and 1.36 [95% CI, 1.06-1.75] for T2; both versus T1; estimated glomerular filtration rate slope: T3, -3.19 [95% CI, -3.66 to -2.72] mL/min per 1.73 m2 per y, T2, -2.08 [95% CI, -2.52 to -1.63] and T1 -2.35 [95% CI, -2.79 to -1.91]; P=0.002). The benefit of dapagliflozin was consistent regardless of baseline ET-1, and the placebo-corrected decrease in ET-1 with dapagliflozin was 0.13 pg/mL (95% CI, 0.25-0.01; P=0.029). CONCLUSIONS: Higher baseline ET-1 concentration was independently associated with worse clinical outcomes and more rapid decline in kidney function. The benefit of dapagliflozin was consistent across the range of ET-1 concentrations measured, and treatment with dapagliflozin led to a small decrease in serum ET-1 concentration. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03036124.
引用
- Yeoh, Docherty, Campbell, et al. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. Circulation. 2023. PMID: 37039015. doi:10.1161/CIRCULATIONAHA.122.063327
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。